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Quantitative differences in serum neutralizing-antibody (SNAb) responses to rabies vaccination and survival
after a rabies challenge infection between two inbred mice strains, C3H/J and C57BL/6J, were shown to be
under genetic control. A 99% confidence limit calculated from the SNAb response titers of 14 C57BL/6J mice
resulted in an upper limit for the SNAb respone titer of C57BL/6J mice at 50.63. A SNAb titer -50.63 in
response to rabies vaccination was assigned the phenotype of hyporesponder, and a SNAb titer >50.63 in
response to rabies vaccination was assigned the phenotype of hyperresponder in this study. The hyper-SNAb
response to rabies vaccination and the higher frequency of survival after rabies challenge infection behave as
Mendelian dominant alleles in F1 hybrids (C3H/J x C57BL/6J) and backcross (BC) (F1 [C3H/J x C57BL/6J]
x C57BL/6J) progeny. Both a relatively hyper-SNAb response and a higher frequency of vaccine-inducible
survival phenotypes occur in C3H/J mice. On the other hand, both the relatively hypo-SNAb response and a
lower frequency of vaccine-inducible survival phenotypes behave as Mendelian recessive alleles and occur in
C57BL/6J mice. C3H/J mice are H-2 Kk, and C57BL/6J mice are H-2 Kb. All three phenotypic traits (H-2 type,
SNAb response, and survival after rabies challenge infection) segregate as independent (unlinked) monogenic
traits in BC progeny (F1 [C3H/J x C57BL/6J] x C57BL/6J). The genetically controlled survival trait is
inducible by rabies vaccination, but SNAb response is not a parameter that measures successful vaccine
induction of preexposure protection from a rabies challenge infection in the BC progeny. The essential role of
vaccination in developing preexposure protection in genetically responsive mice is confirmed, but indicates that
in vitro measurements other than SNAb titers need to be developed to identify mice that have failed to achieve
preexposure protection by rabies vaccination. This study confirms Lodmell's findings (D. L. Lodmell and B.
Chesebro, J. Virol. 50:359-362, 1984; D. L. Lodmell, J. Exp. Med. 157:451-460, 1983) that susceptibility to
rabies infection is genetically controlled in some mice strains. Additionally, this study indicates that
conventional rabies vaccination even with more potent vaccines may not induce protection from infection in
some genetically susceptible individuals.
The greatest scientific contribution to the treatment of
rabies infection in humans was Pasteur's report of the
development in 1884 of the first rabies vaccine, which
consisted of dessicated spinal cord from rabies-infected
rabbits (13). The application of rabies vaccine to animals,
especially domestic dogs, for preexposure protection has
been the primary reason for the reduction of the incidence of
human rabies infection (23). Shortly after Pasteur's success-
ful human rabies vaccination, Babes and Lepp showed that
antibody to rabies correlated with protection from rabies
infection (1). Therefore, most investigators have sought the
protection of a rabies vaccination that is better at inducing
antibody production specific for rabies virus either pre- or
postexposure (14). This search has resulted in a sequential
development of various rabies vaccines produced in either
mammalian central nervous system tissue or avian embryos.
The problems associated with these earlier rabies vaccines
have been detailed elsewhere (14). Rabies vaccines derived
from diploid cell culture were developed to overcome the
side effects or variability of antigen content experienced with
the mammalian brain- or avian-embryo-derived rabies vac-
cines. These diploid vaccines stimulate a high rate of
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seroconversion with minimal side effects (2, 15, 24). It
appears that in the future, rabies virus external-surface
glycoprotein analogs that might be better neutralizing-
antibody stimulators can be biosynthesized from cloned
rabies DNA sequences in Escherichia coli (26) and used in
vaccines.
Although the newer rabies vaccines stimulate seroconver-
sion at a high frequency, there still remain a few humans in
some trials who do not produce a high titer of serum
neutralizing-antibody (SNAb) after vaccination (2, 4, 19).
Because of conflicting results in animals, it is not clear if
these individuals are more susceptible to rabies infection
than are individuals that seroconvert with a high titer after
vaccination. With animals, some data indicate that a SNAb
titer is the fulcrum for protection from rabies infection (6, 12,
25). In contrast, other available data show that SNAb titers
are not consistent indicators of protection from rabies infec-
tion in animals (3, 17, 20).
In a preliminary study of human SNAb response to a duck
embryo-derived rabies vaccine, we observed a significant
association of HLA-B7 with a low level (titer of <1:4) of
SNAb response (R. M. Sharp, C. A. Holmberg, L. H. Rus-
sell, and J. W. Templeton, unpublished data). The study
could not be concluded because the production of duck
embryo-derived rabies vaccine for human use was discon-
tinued. Since considerable homology of the human HLA
complex and mouse H-2 complex exists (5), our interest was
to develop a genetic model for SNAb hypo- and hyper-
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GENETIC CONTROL OF RESISTANCE TO RABIES INFECTION 99
responses to rabies vaccination in inbred mice strains. With
a genetic model, we wanted to determine if mice that were
genetically controlled SNAb hyporesponders to rabies vac-
cination were more susceptible to infection from a rabies
virus challenge. The advantages of utilizing mice for these
studies are that (i) inbred strains allow the best opportunity
to determine the mode of inheritance of genetically con-
trolled immune mechanisms of resistance to rabies infection
in a mammalian species; and (ii) mice can be challenged with
live virus with the least amount of risk to personnel and with
the accompanying expectation that the experimental findings
are relevant to field situations of rabies exposure.
The data reported here indicate that in this model system,
both SNAb response to rabies vaccination and resistance to
rabies challenge infection are controlled by single genes.
SNAb hyper- and hyporesponses to rabies vaccination are
controlled by dominant and recessive alleles, respectively,
and survival after rabies challenge infection is dominant to
nonsurvival. These genes are not linked to each other, and
they are not linked to H-2.
MATERIALS AND METHODS
Mice. AKR/J, C3H/J, and C57BL/6J mice were obtained
from Roscoe B. Jackson Laboratories, Bar Harbor, Maine.
BALB/cAnTexAm and DBA/2TexAm mice were obtained
from Texas Inbred Mouse Co., Houston, Tex. Outbred
Swiss mice were obtained from Charles River Breeding
Laboratories, Inc., Wilmington, Mass. B10.SM (70NS)/Sn
mice were obtained from James E. Womack, Department of
Veterinary Pathology, Texas A&M University, College Sta-
tion. The F1 and backcross (BC) progeny were produced in
our laboratories. The mice used in these experiments were 7
to 12 weeks of age at the time of vaccination.
Vaccine. The rabies vaccine used in this study was pro-
vided by G. H. Burgoyne, Michigan Department of Public
Health. The vaccine is derived from a rhesus diploid cell line
(2). In a preliminary experiment, the dose used was 60 pul of
a 1:7.5, 1:15, 1:30, 1:60, or 1:90 dilution of the vaccine in
Dulbecco modified minimal essential medium. In the exper-
iments with parental strains (C3H/J and C57BL/6J) and F1
(C3H/J x C57BL/6J ) mice, 60 pul of a 1:30, 1:60, or 1:90
dilution of vaccine was used. A 60-,ul volume of 1:60 dilution
of vaccine was used to inoculate the BC progeny (F1 [C3H/J
x C57BL/6J] x C57BL/6J). Two inoculations 7 days apart
were used for immunization. All immunizations were given
intramuscularly in the hind limb. The various vaccine doses
could discriminate between hypo- and hyper-SNAb respond-
ers with no significant variation in SNAb titers in the
parental strains and F1 mice, so the data for the different
vaccine doses were pooled.
SNAb titers. The SNAb response to rabies vaccination
was quantitated by a modification of the rapid fluorescent-
focus inhibition test, with the BHK-13s cell line as target
indicator cells (22). The test was modified by using a 24-well
microtiter plate instead of an 8-well culture slide. The
reagent volumes were doubled to correspond to the in-
creased culture surface area. The rabies strain used was
CVS-11, obtained from the Texas Department of Health.
The BHK-13s cells were inoculated with CVS-11 at a virus
titer ranging from 40 to 68 50% tissue culture infective doses
per 0.1 ml. The test sera were diluted 1:10, 1:50, 1:500, and
1:5,000. The serum from each experiment was assayed for
SNAb titer in the same test. A U.S. standard rabies immune
globulin, obtained from Division of Control Activities, Bu-
reau of Biologics, Food and Drug Administration, Public
Health Services, Department of Health, Education, and
Welfare, Rockville, Md. 20852, was utilized as a control
antiserum in each test. The inoculated BHK-13s cells were
stained with a fluorescein-conjugated antibody to rabies
virus obtained from BBL Microbiology Systems, Cockeys-
ville, Md. (lot no. AZGCOF). The cells were fixed with a
mixture of 85 parts acetone, 15 parts ethanol, and 5 parts
water. The 50% serum neutralization endpoint titer was
determined by the method of Reed-Muench (18) from the
number of fluorescent foci in 20 fields. The SNAb titers were
determined for each mouse in the study, with ear tags to
identify individual mice. All titers presented in this paper are
reciprocal titers.
H-2 serotyping. The H-2 antigens on peripheral blood
lymphocytes were determined by a two-stage micro-
cytotoxicity test (11). Low-Tox-M rabbit complement was
obtained from Accurate Chemical and Scientific Corp.,
Westbury, N.Y. The H-2 Kk and Kb antisera were obtained
from S. Rich, Baylor College of Medicine, Houston, Tex.,
and J. VandeBerg, Southwest Foundation for Biomedical
Research, San Antonio, Tex. The H-2 Kb reagents are
National Institutes of Health antisera designated E-28b and
la. 9,20 (catalog no. Y1-8-03-29-02). The H-2 Kk reagents are
National Institutes of Health antisera designated anti-Kk
control serum (catalog no. Y1-9-03-15-03) and D-25. The
antisera were used at dilutions of 1:100 and 1:200.
Rabies challenge infection. The viral challenge was done
with a CVS-11 rabies virus harvested from BHK-13s cells
grown in Dulbecco modified minimal essential medium with
10% fetal calf serum. The challenge procedure developed
was the subcutaneous inoculation in the ventral cervical
region of a single virus lot containing 3.5 x 105 tissue culture
infective doses in 0.1 ml. The animals were observed daily
for a minimum of 28 days for symptoms of rabies infection.
Nonvaccinated mice died between 8 and 14 days post-
challenge inoculation.
Statistical analysis. The chi-square test, Fisher exact test,
and Wilcoxon test for two-sample rank testing were used to
determine statistical significance.
RESULTS
Selection of rabies vaccine dose and inbred strains for study.
In a preliminary study in BALB/cAnTexAM mice with five
dilutions of the human vaccine (1:7.5, 1:15, 1:30, 1:60, and
1:90), it was determined that the 1:60 and 1:90 vaccine
dilutions discriminated between response and nonresponse,
respectively, of SNAb in this strain. The optimal bleeding
times for two intramuscular inoculations 7 days apart of 60
p1l of the 1:60 and 1:90 dilutions were 14 and 21 days
post-second immunization (data not shown).
Utilizing this immunization schedule, another preliminary
study was conducted in five inbred strains (AKR/J,
BALB/cAnTexAm, C3H/J, C57BL/6J, and DBA/2TexAm),
one cogenic strain [B1O.SM (70NS)/Sn] and one group of
Swiss outbred mice. Each strain and the Swiss mice were
divided into two groups of four mice. One group was
inoculated two times 1 week apart with 60 [lI of a 1:60
dilution of vaccine, and the other group was inoculated two
times 1 week apart with 60 pI of a 1:90 dilution of vaccine.
The SNAb titers were measured at 14 days post-second
immunization. Two inbred strains (C3H/J and C57BL/6J)
were selected for further studies. The geometric mean titers
(GMT) of the C3H/J in the 1:60 and 1:90 vaccine dilution
groups were 113.8 and 195.4, respectively. The C57BL/6J
mice had GMT of 27.3 and 19.1 with 1:60 and 1:90 vaccine
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100 TEMPLETON ET AL.
TABLE 1. SNAb response of C3H/J and C57BL/6J parental
strains and F1 (C3H/J x C57BL/6J) mice to three dilutions of
rabies vaccine
SNAb GMT at vaccine dilution of:
Mouse strain
1:30 1:60 1:90
C3H/Ja 158.0 157.8 96.4
C57BL/6J 14.1 22.3 15.4
F1 (C3H/J x C57BL/6J)b 107.4 110.0 98.3
a SNAb titers at each dilution are significantly higher (P < 0.01) for C3H/J
mice than for C57BL/6J mice but not significantly different from F1 mice.
b SNAb titers at each dilution are singificantly higher (P < 0.01) for F1 mice
than for C57BL/6J mice.
dilutions, respectively. Four mice from each strain (two
from the 1:60 and two from the 1:90 vaccine dilution groups)
were immunized a third time, 31 days after the second
immunization, with a 1:60 dilution of vaccine (data not
shown). The SNAb titers were determined at 14-days post-
immunization. The SNAb responses of the two strains were
comparable to the SNAb responses from the first immuni-
zations, although the titers uniformly increased. The GMT
was 1,428 for the C3H/J mice and 89 for the C57BL/6J mice.
These latter data indicate that the relatively hyper- and
hyporesponses of the C3H/J and C57BL/6J mice, respec-
tively, do not indicate a difference in immunization timing
requirements for effective antibody respone to the vaccine
by the two strains.
The parental strains (C3H/J and C57BL/6J) and the F1
(C3H/J x C57BL/6J) mice were clearly distinguishable as
hyper- or hyporesponders with a 1:30, 1:60, or 1:90 dilution
of the vaccine dose (Table 1). There is no significant differ-
ence in the SNAb response of the parental strain, C3H/J, and
the F1 (C3H/J x C57BL/6J) mice to the various dilutions of
rabies vaccine, but both groups have significantly higher
SNAb responses compared with the other parental strain,
C57BL/6J.
Genetics of SNAb response. The C3H/J and C57BL/6J
strains were assigned the phenotypes of hyper-SNAb re-
sponder, respectively. With these two strains as parents, the
F1 hybrids (Table 2) and the BC (F1 x C57BL/6J) mice
(Table 3) were produced. The SNAb titer responses of the F1
hybrids were not significantly different from those of the
C3H/J parental strain (Table 2). These data indicate that a
dominant gene(s) controls SNAb response. Based on the
data in Table 2, the BC matings were made to the C57BL/6J
strain, and the SNAb titers were determined. The BC
progeny were assigned the phenotype of hyper- or
hyporesponder based on their individual SNAb titers. A 99%
confidence limit calculated from the SNAb titers of 14
C57BL/6J mice resulted in an upper limit for SNAb titer
hyporesponsiveness of 50.63 in the C57BL/6J strain. A
TABLE 2. SNAb titers in C3H/J and C57BL6J parental strains
and F1 (C3H/J x C57BL/6J)
No. of SNAb GMT
Mouse strain
mice tested (range)
C3H/Ja 15 134.34 (12-616)
C57BL/6Jb 14 17.8 (10-50)
F1 (C3H/J x C57BL/6J) 23 108.8 (22-1,390)
a SNAb titers of the C3H/J mice are significantly higher than those of the
C57BL/6J mice (P < 0.001), but not significantly different than those of the F1
mice (0.0735 < P < 0.0749).
b SNAb titers of the F1 mice are significantly higher than those of the
C57BL/6J mice (P < 0.001).
TABLE 3. Segregation of SNAb titers in BC progeny of F,
(C3H/J x C57BL/6J) x C57BL/6J mice
Phenotype No. of BC SNAb GMTprogeny (range)
Hyperresponder 19 153.3 (62-406)
Hyporesponder' 18 24.9 (22-50)
a BC mice were considered hyperresponder if they had a SNAb titer of
>50.63, which is the upper 99% confidence limit of SNAb titer response to
human rabies vaccination in 14 C57BL/6J mice.
SNAb titer -50.63 was assigned the phenotype of
hyporesponder. In the BC progeny, 17 of 19 mice assigned
the hyperresponder phenotype had SNAb titers >100, and of
the two BC progeny with SNAb titers of <100, one had a
SNAb titer of 97, and one had a SNAb titer of 62. In the BC
progeny assigned the phenotype of hyporesponder, 16 of 18
mice had SNAb titers of <23, and of the two with SNAb
titers >23 but <50.63, one had a SNAb titer of 38, and one
had a SNAb titer of 50. If these two hyporesponders with
SNAb titers of >23 but <50.63 were misassigned and should
have been assigned phenotypes of hyperresponders, the BC
segregation ratio is still not altered enough to reject the
hypothesis that a single dominant allele is controlling the
SNAb response to the rabies vaccine. The data in Table 3 fit
a segregation ratio of 1:1, which is expected if $NAb
response to the rabies vaccine is controlled by a monogenic
dominant allele (X2 = 0.03, 1 df).
Survival after rabies challenge infection. A series of pre-
liminary trials of live-virus peripheral challenge was per-
formed (data not shown). It was determined that a subcuta-
neous inoculation of live challenge virus in the ventral
cervical area resulted in a uniform death rate for all nonvac-
cinated mice. After vaccination, the C3H/J and F1 (C3H/J x
C57BL/6J) mice were relatively resistant, and the C57BL/6J
mice were relatively susceptible to the live-virus challenge
(Table 4). The percentage of immunized F1 (C3H/J x
C57BL/6J) survivors of the rabies challenge infection is not
statistically different (P = 0.6737) from the survival rate of
the immunized C3H/J parental strain, indicating that a dom-
inant gene(s) controls survival.
Mode of inheritance of SNAb response to rabies vaccination
and of survival after rabies challenge infection and linkage of
H-2. In the first experiment, the linkage of H-2 to survival
was tested in a BC of the F1 (C3H/J x C57BL/6J) to the
C57BL/6J parental strain (Table 5). We reject the hypothesis
of linkage between H-2 and survival after a rabies challenge
infection (X2 = 1.45, 1 df). Based on the facts that H-2 Kk and
H-2 Kb are codominant gene traits and that SNAb response
to rabies vaccination and survival after rabies challenge
infection behave as dominant gene traits in the F1, a trihybrid
TABLE 4. Survival of C3H, C57BL/6J, and F1 (C3H/J x
C57BL/6J) mice after challenge infection with rabies virus
No. of mice surviving/no. of mice
Mouse strain challenged
Not vaccinated Vaccinated
C3H/Ja 0/8 9/12
C57BL/6Jb 0/8 1/12
F1 (C3H/J x C57BL/6J) 0/11 4/5
a The survival rate of vaccinated C3H/J mice is significantly higher than that
of vaccinated C57BL/6J mice (P = 0.0014), but not significantly different than
that of the vaccinated F1 mice (P = 0.6737).
b The survival rate of the vaccinated C57BL/6J mice is significantly lower
than that of the vaccinated F1 mice (P = 0.0097).
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GENETIC CONTROL OF RESISTANCE TO RABIES INFECTION 101
TABLE 5. Segregation of H-2 and survival after a rabies
challenge infection in BC [F1 (C3H/J x C57BL/6J) x C57BL/6J]
progeny
No. of mice
Genotype
Survivinga Not surviving
H-2k/b 25b 16
H-2b/b 16 18
a x2 =0.65 1 df, for rejection of a 1:1 segregation ratio of both H-2 Kk and
survival versus death after rabies challenge infection.
b x2= 1.45, 1 df, for acceptance of linkage between H-2 K and survival after
rabies challenge infection.
BC between F1 (C3H/J x C57BL/6J) x C57BL6/J was made,
and the phenotypes of the BC progeny were scored (Table
6). The chi-square test is partitioned to test for goodness of
fit of each individual trait to a 1:1 segregation ratio and for
linkage between any of the traits. The results of these
statistical tests allow us to accept the hypotheses that H-2,
SNAb response to vaccination, and survival after rabies
challenge infection segregate as monogenic, unlinked traits
in the BC (F1 [C3H/J x C57BL/6J] x C57BL6/J) progeny.
Thus, SNAb hyper- and hyporesponses are controlled by
dominant and recessive alleles, respectively, and survival
after rabies challenge infection is dominant to nonsurvival.
DISCUSSION
In this study we found that the quantitative difference in
SNAb response to rabies vaccination between two inbred
strains of mice (C3H/J and C57BL/6) is controlled by a single
gene, and the hyper-SNAb response to rabies vaccination is
controlled by a dominant allele. This SNAb response gene is
not linked to H-2. Survival after a rabies challenge infection
in these two strains is controlled by a dominant allele, and
the rabies survival gene is not linked to the H-2 or the SNAb
response gene.
The evidence for genetic control of SNAb response to
rabies vaccination and survival after rabies challenge infec-
tion was obtained by genetic studies between two inbred
strains. The strains selected for genetic analysis were C3H/J
TABLE 6. Analysis of segregationa and linkageb of H-2
haplotypes, SNAb response to rabies vaccination, and survival
after rabies challenge infection in BC [F1 (C3H/J x C57BL/6J) x
C57BL/6J] progeny
Response to challenge infection
H-2 haplotypec Survival Death
and SNAb
responsed No. of BC GMT No. of BC GMT Days until
progeny progeny death
blk
+ 6 123 8 157 8-14
- 5 27 4 23 10
bib
+ 1 149 4 148 10-12
- 2 23 7 25 10-12
a x2 values for 1:1 segregation ratios of: H-2k and H-2b = 2.189 with 1 df;
SNAb hypo and hyperresponses = 0.027 with 1 df; survival or death after
rabies challenge infection = 2.189 with 1 df.
b x2 values for linkage of: H-2 with SNAb response = 2.189 with 1 df; H-2
with survival after rabies challenge infection = 0.243 with 1 df; SNAb
response with survival after rabies challenge infection = 0.027 with 1 df. x2
value for independent assortment of alleles at three loci = 0.676 with 1 df.
c H-2 haplotypes: C3HIJ = H-2k = k, and C57BL/6J = H-2b = b.
d +, SNAb hyperresponders with individual SNAb titers of >50.63; -,
SNAb hyporesponders with individual SNAb titers of s50.63.
and C57BL/6J. In surveying several different inbred strains
to determine if there were quantitative differences in SNAb
responses to rabies vaccination, the C3H/J strain was se-
lected as consistently responding to vaccination with high
SNAb titers compared with the other inbred strains tested,
and the C57BL/6J strain was selected as a consistently low
responder compared with the other inbred strains tested in a
series of preliminary studies (data not shown). Based on
these data, the C3H/J strain was assigned the phenotype of
hyper-SNAb responder, and the C57BL/6J strain was as-
signed the phenotype of hypo-SNAb responder. With these
two inbred strains as the parental strains, F1 and BC progeny
were produced for genetic analysis of the SNAb response to
rabies vaccination. The phenotypic ratios of SNAb re-
sponses in the F1 and BC progeny (Tables 2 and 3) fit the
expected ratios for a monogenic mode of inheritance for
SNAb response to rabies vaccination. The hyper-SNAb
response behaves as a dominant allele, and the hypo-SNAb
response behaves as a recessive allele.
The question we addressed was whether or not the sur-
vivability of an individual challenged with a rabies infection
is dependent on the SNAb response to rabies vaccination.
The method of challenge infection adopted for this study was
uniformly lethal in all unimmunized mice tested, regardless
of strain (data not shown). In the strains we tested, it was
also shown that 100% of the unimmunized C3H/J, C57BL/6J,
and F1 (C3H/J x C57BL/6J) mice died by our method of
rabies challenge infection (Table 5). The C3H/J and F1
(C3H/J x C57BL/6J) mice were protected from rabies chal-
lenge infection by rabies vaccination at a higher frequency
than the C57BL/6J mice. The phenotype of hyper-SNAb
response to rabies vaccination and a higher frequency of
inducible protection from rabies challenge infection by vac-
cination occur together in the C3H/J and segregate in the F1
(C3H/J x C57BL/6J) strains as a dominant gene(s) trait.
C3H/J mice are H-2 Kk, and C57BL/6J mice are H-2 Kb.
However, in the BC (F1 [C3H/J x C57BL/6J] x C57BL/6J),
these phenotypes (hyper-SNAb response, H-2 K locus, and
inducible survival after rabies challenge infection) segregate
as unlinked monogenic traits (Table 5 and 6). Therefore,
these data indicate that inducible survival after rabies chal-
lenge infection and hyper-SNAb response in these two
strains of mice are separate, independent functions.
The role of genetic control of survivability in inbred
strains of mice after rabies challenge infection has been
extensively studied by Lodmell (7, 8). Data from both of his
studies and this study are consistent with few genes control-
ling survivability after rabies infection in mice. Due to the
different challenge methods and lack of appropriate genetic
studies, it is not known if the same genes are controlling
survival in Lodmell's challenge experiments and in these
reported challenge experiments. A contrasting point is that
we do not observe any difference in survivability between
sexes as reported by Lodmell (8), but this finding may be due
to the fact that our challenge infection procedure is more
rigorous, since vaccination is essential for survival in our
studies (Table 4), and we may not have investigated the
appropriate strains. Lodmell (8) reported that many of the
mice in his study did not die from the challenge infection, but
did suffer from secondary effects of the challenge infection,
principally paralysis. He labeled these mice nonrecovered
survivors. Those mice which recovered and demonstrated
no secondary effects of the challenge infection he labeled
recovered survivors. All of the mice in our challenge infec-
tion studies exhibited behavioral changes. These changes
initially included agitation, marked by increased motion, and
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102 TEMPLETON ET AL.
some exhibited depression characterized by loss of appetite
and recumbency. The agitation was first observed on day 6
after challenge. None of the survivors exhibited agitation or
depression after day 12 postchallenge. There was no obvious
permanent neurological damage exhibited by the survivors,
whereas Lodmell (8) observed a large variation between
strains in terms of secondary effects of the challenge infec-
tion.
Other investigators have questioned the role of SNAb in
protection (3, 17, 20), and our data support the concept that
SNAb alone does not afford immune protection to rabies
infection. These data do not provide arguments against the
current prophylaxis of rabies vaccination for preexposure
protection or postexposure treatment. In fact, rabies vacci-
nation was crucial for protection from rabies infection. The
data do support, however, a need to study the mechanisms
of immune protection to rabies infection to find an in vitro
parameter that correlates better than SNAb titer with im-
mune protection. This need seems obvious, as we have mice
that have been vaccinated preexposure, have responded
with high SNAb titers, and yet were vulnerable to rabies
challenge infection (Table 6).
The complexity of host resistance to rabies infection has
been stated by others (8). The essential role of cytotoxic-T-
cells in protection from rabies infection has been demon-
strated (9, 10, 16, 21). Although our studies did not provide
information concerning immune mechanisms other than the
role of SNAb, the protection induced by vaccination to our
challenge method is long term, since comparable survival
rates were observed in mice challenged 1, 2, or 6 months
after the second vaccination (data unpublished). These data
indicate that immunologic memory is being developed by the
vaccine-induced protection. This finding does not argue for a
pure cytotoxic-T-cell-derived protection, but supports the
evidence of others (9, 10, 21) that a cytotoxic-T-cell response
is a crucial component of immune protection to rabies
infection.
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